Page last updated: 2024-11-13
sj733
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
SJ733: antimalarial; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 89508529 |
CHEMBL ID | 4207489 |
SCHEMBL ID | 14871903 |
MeSH ID | M000605088 |
Synonyms (23)
Synonym |
---|
SCHEMBL14871903 |
HY-19556 |
CS-8066 |
1424799-20-1 |
unii-vt3a7na96k |
sj733 |
sj-733 |
(+)-sj733 |
VT3A7NA96K , |
DB12659 |
(3s,4s)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (3-cyano-4-fluoro-phenyl)-amide |
(3s,4s)-n-(3-cyano-4-fluorophenyl)-1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide |
(+)-sj557733 |
(3s,4s)-n-(3-cyano-4-fluorophenyl)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide |
gtpl9723 |
(+)-sj000557733 |
sj000557733 |
Q27292006 |
MS-28639 |
CHEMBL4207489 |
vkcpfwktfzaoto-lewjyisdsa-n |
EN300-22861442 |
AKOS040742855 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
"Two multidose unboosted cohorts (n = 9) (SJ733, 300 mg and 600 mg daily for 3 days) followed by three single-dose boosted cohorts combining SJ733 (n = 18) (75-, 300-, or 600-mg single dose) with cobicistat (150-mg single dose) as a pharmacokinetic booster were evaluated in healthy volunteers (ClinicalTrials." | ( Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. Bebrevska, L; Branum, KC; Chalon, S; Dallas, RH; Flynn, PM; Freeman, BB; Gaur, AH; Gusovsky, F; Guy, RK; Hammill, JT; Heine, RN; John, E; Maki, N; McCarthy, JS; Ost, S; Panetta, JC; Patel, ND; Richardson, JL; Smith, AM; Stewart, TB; Tang, L; Yanagi, T, 2022) | 1.39 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Single dose PK studies of SJ733 in mice, rats, and dogs demonstrated appreciable oral bioavailability (60-100%), whereas SJ311 had lower oral bioavailability (mice 23%, rats 40%) and higher renal clearance (10-30 fold higher than SJ733 in rats and dogs), suggesting less favorable exposure in humans." | ( Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones. Charman, SA; Chen, Y; Freeman, B; Guy, RK; Hammill, J; Holbrook, G; Mirsalis, JC; O'Loughlin, KG; Shackleford, DM; White, KL; Yang, L; Zhu, F, 2021) | 0.92 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (25)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1412522 | Antimalarial activity against GFP transfected Plasmodium berghei in ICR mouse engrafted with parasite infected erythrocytes assessed as reduction in parasitemia administered as po qd for 3 to 5 days post infection measured on day 3 to 30 by Giemsa stainin | 2018 | MedChemComm, Mar-01, Volume: 9, Issue:3 | Recent updates in the discovery and development of novel antimalarial drug candidates. |
AID1375190 | Antimalarial activity against wild type Plasmodium falciparum Dd2 | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ |
AID1412523 | Oral bioavailability in mouse at 15 mg/kg | 2018 | MedChemComm, Mar-01, Volume: 9, Issue:3 | Recent updates in the discovery and development of novel antimalarial drug candidates. |
AID1629028 | Selectivity ratio of EC50 for multi-drug resistant Plasmodium falciparum V1S to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D7 | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1629008 | Antimalarial activity against chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in parasite growth after 72 hrs by Sybr green dye based spectrophotometry | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1412521 | Antimalarial activity against Plasmodium falciparum 3D7 0087/N9 in NODscid IL-2Rgammanull mouse engrafted with parasite infected human erythrocytes assessed as reduction in parasitemia administered via oral gavage starting from day 3 to day 6 post infecti | 2018 | MedChemComm, Mar-01, Volume: 9, Issue:3 | Recent updates in the discovery and development of novel antimalarial drug candidates. |
AID1629019 | Antimalarial activity against Plasmodium berghei NK65 ANKA infected in Swiss Webster mouse assessed as reduction in parasitemia at 200 mg/kg, po qd administered as single dose by Peters test | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1629020 | Antimalarial activity against Plasmodium berghei NK65 ANKA infected in Swiss Webster mouse assessed as reduction in parasitemia at 50 mg/kg, po qd for 4 days by Peters test | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1629025 | Selectivity ratio of EC50 for bc1 complex inhibitor resistant Plasmodium falciparum SB-1 A6 to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D7 | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1629023 | Toxicity in Swiss Webster mouse infected by Plasmodium berghei NK65 ANKA assessed as overt signs at 200 mg/kg, po qd administered as single dose | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1779234 | Antimalarial activity against synchronous ring stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | Discovery and development of 2-aminobenzimidazoles as potent antimalarials. |
AID1412524 | Oral bioavailability in Sprague-Dawley rat at 20 +/- 0.2 mg/kg administered via gavage as solution | 2018 | MedChemComm, Mar-01, Volume: 9, Issue:3 | Recent updates in the discovery and development of novel antimalarial drug candidates. |
AID1375187 | Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring ATP4 S358S mutant | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ |
AID1629022 | Toxicity in Swiss Webster mouse infected by Plasmodium berghei NK65 ANKA assessed as overt signs at 50 to 200 mg/kg, po qd for 4 days | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1629016 | Intrinsic clearance in CD-1 mouse liver microsomes after 0.5 to 4 hrs in presence of NADPH by UPLC-MS analysis | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1629015 | Half life in CD-1 mouse liver microsomes in presence of NADPH by UPLC-MS analysis | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1779239 | Selectivity index, ratio of IC50 for antimalarial activity against PfATP4 inhibitor SJ557733-resistant Plasmodium falciparum Dd2 to IC50 of antimalarial activity against Plasmodium falciparum Dd2 | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | Discovery and development of 2-aminobenzimidazoles as potent antimalarials. |
AID1412526 | Oral bioavailability in beagle dog at 3 mg/kg | 2018 | MedChemComm, Mar-01, Volume: 9, Issue:3 | Recent updates in the discovery and development of novel antimalarial drug candidates. |
AID1629027 | Selectivity ratio of EC50 for multi-drug resistant Plasmodium falciparum Tm90C2b to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D7 | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1629026 | Selectivity ratio of EC50 for mefloquine resistant Plasmodium falciparum D10 to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D7 | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1375195 | Resistance index, ratio of IC50 for drug-resistant Plasmodium falciparum Dd2 harboring ATP4 S358S mutant to IC50 for wild type Plasmodium falciparum Dd2 | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ |
AID1412525 | Oral bioavailability in Sprague-Dawley rat at 17 +/- 0.2 mg/kg administered via gavage as suspension | 2018 | MedChemComm, Mar-01, Volume: 9, Issue:3 | Recent updates in the discovery and development of novel antimalarial drug candidates. |
AID1629024 | Selectivity ratio of EC50 for multi-drug resistant Plasmodium falciparum K1 to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D7 | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. |
AID1412527 | Oral bioavailability in beagle dog at 30 mg/kg | 2018 | MedChemComm, Mar-01, Volume: 9, Issue:3 | Recent updates in the discovery and development of novel antimalarial drug candidates. |
AID1779238 | Antiplasmodial activity against PfATP4 inhibitor SJ557733-resistant Plasmodium falciparum Dd2 assessed as reduction in parasite growth incubated for 72 hrs by Griffith assay based fluorescence analysis | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | Discovery and development of 2-aminobenzimidazoles as potent antimalarials. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (45.45) | 24.3611 |
2020's | 6 (54.55) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 26.44
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.44) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (9.09%) | 5.53% |
Reviews | 1 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (81.82%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |